A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes Mellitus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hoffmann-La Roche
- Last updated on ClinicalTrials.gov
- November 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Arizona Liver Health - Tucson · Tucson, AZ
California · 3
- Orange County Research Center · Lake Forest, CA
- Prospective Research Innovations Inc. · Rancho Cucamonga, CA
- Encompass Clinical Research · Spring Valley, CA
Connecticut · 1
- Chase Medical Research · Waterbury, CT
District of Columbia · 1
- Emerson Clinical Research Institute · Washington D.C., DC
North Carolina · 2
- Accellacare of Piedmont Healthcare · Statesville, NC
- Accellacare of Wilmington, LLC · Wilmington, NC
Pennsylvania · 1
- Tristar Clinical Investigations · Philadelphia, PA
Virginia · 1
- Manassas Clinical Research Center · Manassas, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.